Abbott Laboratories
US.ABT
108.33
-0.46
-0.42%
Abbott Laboratories
108.33
-0.46
-0.42%
Live - 104 symbols - heartbeat 262s ago
· 2026-09-04 20:02
Pre-market
107.99
-0.73%
After-hours
108.33
0.00%
Overnight
108.50
-0.27%
Revenue annual, last 8 years
Latest year +5.67% YoY
Margins
- Gross margin
- 56.42%
- Operating margin
- 18.17%
- Net margin
- 14.72%
Key ratios & quality
- Enterprise value
- 191.44B
- Altman Z-Score
- 5.07
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 5.07, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 30.58B | 31.90B | 34.61B | 43.08B | 43.65B | 40.11B | 41.95B | 44.33B |
| Gross profit | 17.87B | 18.67B | 19.61B | 24.54B | 24.51B | 22.13B | 23.24B | 25.01B |
| Selling & admin expenses | 9.74B | 9.77B | 9.70B | 11.32B | 11.25B | 10.95B | 11.70B | 12.33B |
| Research & development | 2.30B | 2.44B | 2.42B | 2.74B | 2.89B | 2.74B | 2.84B | 2.94B |
| Operating profit | 3.65B | 4.53B | 5.36B | 8.43B | 8.36B | 6.48B | 6.83B | 8.05B |
| Pretax profit | 2.87B | 4.08B | 4.97B | 8.21B | 8.31B | 6.66B | 7.01B | 8.47B |
| Tax | 539.00M | 390.00M | 497.00M | 1.14B | 1.37B | 941.00M | -6.39B | 1.94B |
| Net profit | 2.37B | 3.69B | 4.50B | 7.07B | 6.93B | 5.72B | 13.40B | 6.52B |
| Basic EPS | 1 | 2 | 3 | 4 | 4 | 3 | 8 | 4 |
| Diluted EPS | 1.33 | 2.06 | 2.50 | 3.94 | 3.91 | 3.26 | 7.64 | 3.72 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 10.36B | 11.14B | 11.37B | 11.46B | 11.16B | 12.59B |
| Gross profit | 5.89B | 6.29B | 6.29B | 6.54B | 6.27B | 7.27B |
| Selling & admin expenses | 3.06B | 3.09B | 3.05B | 3.13B | 3.74B | 4.03B |
| Research & development | 716.00M | 725.00M | 766.00M | 735.00M | 767.00M | 892.00M |
| Operating profit | 1.69B | 2.05B | 2.06B | 2.25B | 1.35B | 1.69B |
| Pretax profit | 1.78B | 2.15B | 2.18B | 2.36B | 1.45B | 1.52B |
| Tax | 453.00M | 371.00M | 536.00M | 582.00M | 372.00M | 596.00M |
| Net profit | 1.33B | 1.78B | 1.64B | 1.78B | 1.08B | 928.00M |
| Basic EPS | 1 | 1 | 1 | 1 | 1 | 1 |
| Diluted EPS | 0.76 | 1.01 | 0.94 | 1.01 | 0.61 | 0.53 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 14.63B | 15.67B | 20.44B | 24.24B | 25.22B | 22.67B | 23.66B | 26.00B |
| Cash & ST investments | 4.09B | 4.14B | 7.15B | 10.25B | 10.17B | 7.28B | 7.97B | 8.94B |
| Inventory | 3.80B | 4.32B | 5.01B | 5.16B | 6.17B | 6.57B | 6.19B | 6.49B |
| Total assets | 67.17B | 67.89B | 72.55B | 75.20B | 74.44B | 73.21B | 81.41B | 86.71B |
| Total current liabilities | 9.01B | 10.86B | 11.91B | 13.11B | 15.49B | 13.84B | 14.16B | 16.50B |
| Short-term debt | 207.00M | 1.48B | 220.00M | 754.00M | 2.25B | 1.08B | 1.50B | 3.03B |
| Long-term debt | 19.36B | 16.66B | 18.53B | 17.30B | 14.52B | 13.60B | 12.63B | 9.90B |
| Total liabilities | 36,451,000,000.00 | 36,586,000,000.00 | 39,545,000,000.00 | 39,172,000,000.00 | 37,533,000,000.00 | 34,387,000,000.00 | 33,513,000,000.00 | 33,942,000,000.00 |
| Total equity | 30.72B | 31.30B | 33.00B | 36.02B | 36.91B | 38.83B | 47.90B | 52.77B |
| Retained earnings | 24.56B | 25.85B | 27.63B | 31.53B | 35.26B | 37.55B | 47.26B | 49.78B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 23.15B | 24.47B | 24.84B | 26.00B | 25.51B | 24.52B |
| Cash & ST investments | 6.84B | 7.28B | 7.73B | 8.94B | 7.30B | 5.60B |
| Inventory | 6.64B | 6.95B | 6.71B | 6.49B | 6.99B | 7.32B |
| Total assets | 81.45B | 84.00B | 84.18B | 86.71B | 110.43B | 109.22B |
| Total current liabilities | 13.00B | 13.44B | 14.58B | 16.50B | 18.38B | 17.81B |
| Short-term debt | 506.00M | 507.00M | 1.35B | 3.03B | 4.41B | 3.01B |
| Long-term debt | 12.74B | 12.93B | 11.60B | 9.90B | 29.64B | 29.60B |
| Total liabilities | 32,384,000,000.00 | 33,170,000,000.00 | 32,917,000,000.00 | 33,942,000,000.00 | 57,728,000,000.00 | 57,453,000,000.00 |
| Total equity | 49.06B | 50.83B | 51.26B | 52.77B | 52.70B | 51.76B |
| Retained earnings | 47.72B | 48.47B | 49.10B | 49.78B | 49.96B | 49.79B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 6.30B | 6.14B | 7.90B | 10.53B | 9.58B | 7.26B | 8.56B | 9.57B |
| Depreciation & amortization | 3.28B | 3.01B | 3.33B | 3.54B | 3.27B | 3.24B | 3.22B | 3.12B |
| Free cash flow | 4.91B | 4.50B | 5.72B | 8.65B | 7.80B | 5.06B | 6.35B | 7.40B |
| Dividends paid | -1.97B | -2.27B | -2.56B | -3.20B | -3.31B | -3.56B | -3.84B | -4.12B |
| Stock buybacks / issuance | -238.00M | -718.00M | -403.00M | -2.30B | -3.80B | -1.23B | -1.30B | -893.00M |
| Ending cash balance | 3.84B | 3.86B | 6.84B | 9.80B | 9.88B | 6.90B | 7.62B | 8.52B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 1.42B | 2.05B | 2.79B | 3.32B | 1.32B | 2.49B |
| Depreciation & amortization | 756.00M | 777.00M | 791.00M | 792.00M | 803.00M | 1.06B |
| Free cash flow | 933.00M | 1.55B | 2.29B | 2.63B | 916.00M | 1.99B |
| Dividends paid | -1.03B | -1.03B | -1.03B | -1.03B | -1.10B | -1.10B |
| Stock buybacks / issuance | -280.00M | -6.00M | -305.00M | -302.00M | -180.00M | -1.05B |
| Ending cash balance | 6.53B | 6.95B | 7.51B | 8.52B | 6.80B | 5.10B |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE % | 7.71 | 11.97 | 14.08 | 20.62 | 19.13 | 15.20 | 31.07 | 13.07 |
| ROA % | 3.30 | 5.46 | 6.40 | 9.57 | 9.27 | 7.75 | 17.33 | 7.76 |
| ROIC % | 5.42 | 8.41 | 9.66 | 13.97 | 13.27 | 10.93 | 23.22 | 10.36 |
| 5-year avg ROE % | 9.35 | 9.79 | 8.46 | 11.25 | 14.70 | 16.20 | 20.02 | 19.82 |
| EBIT margin % | 12.10 | 14.88 | 15.93 | 20.30 | 20.31 | 18.20 | 18.05 | 20.21 |
| FCF / sales % | 16.04 | 14.10 | 16.54 | 20.08 | 17.88 | 12.61 | 15.14 | 16.68 |
| Current ratio | 1.62 | 1.44 | 1.72 | 1.85 | 1.63 | 1.64 | 1.67 | 1.58 |
| Quick ratio | 1.20 | 1.04 | 1.30 | 1.46 | 1.23 | 1.16 | 1.23 | 1.18 |
| Debt / assets | 64.10 | 60.78 | 59.93 | 53.09 | 48.29 | 40.48 | 31.51 | 26.59 |
| LT debt / equity | 63.42 | 56.02 | 59.26 | 50.98 | 42.16 | 37.69 | 28.37 | 20.77 |
| Interest coverage | 4.48 | 7.09 | 10.10 | 16.41 | 15.89 | 11.46 | 13.55 | 18.17 |
| Revenue CAGR (3Y) % | 14.43 | 15.23 | 8.11 | 12.10 | 11.02 | 5.04 | -0.88 | 0.51 |
| Net income CAGR (3Y) % | -18.80 | 38.10 | 111.22 | 44.00 | 23.43 | 8.38 | 23.76 | -2.01 |
| FCF CAGR (3Y) % | 38.27 | 29.27 | 8.88 | 20.80 | 20.16 | -4.03 | -9.78 | -1.78 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE % | 30.82 | 31.10 | 30.80 | 13.07 | 12.44 | 10.67 |
| ROA % | 17.54 | 17.81 | 17.63 | 7.76 | 6.54 | 5.62 |
| ROIC % | 23.67 | 23.94 | 23.81 | 10.36 | 8.68 | 7.79 |
| 5-year avg ROE % | -- | -- | -- | -- | -- | -- |
| EBIT margin % | 18.67 | 19.55 | 19.72 | 20.21 | 19.22 | 17.77 |
| FCF / sales % | 15.72 | 15.72 | 15.78 | 16.68 | 16.35 | 16.80 |
| Current ratio | 1.78 | 1.82 | 1.70 | 1.58 | 1.39 | 1.38 |
| Quick ratio | 1.27 | 1.30 | 1.24 | 1.18 | 1.01 | 0.97 |
| Debt / assets | 27.13 | 26.57 | 25.40 | 26.59 | 65.40 | 63.80 |
| LT debt / equity | 26.09 | 25.57 | 22.76 | 20.77 | 56.93 | 57.92 |
| Interest coverage | 14.40 | 15.90 | 16.99 | 18.17 | 16.18 | 10.81 |
| Revenue CAGR (3Y) % | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) % | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) % | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Medical devices46.48%
Diagnostic Products24.55%
Nutritional Products17.03%
Established Pharmaceutical Products11.90%
Quote time 2026-09-04 20:02:35
For reference only, not investment advice.